Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.

Keywords

Aromatase inhibitor, Tamoxifen, Medicine, Aromatase, Breast cancer

References

• National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.Patricia J. Eifel, Jan Axelson, Janitha Costa — 2001
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancerThe ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group — 2003
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.M Baum, Aman U. Budzar, J Cuzick — 2002
• Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer.Anthony Abner, Abram Recht, T.J. Eberlein — 1993
• Annual hazard rates of recurrence for breast cancer after primary therapy.T Saphner, Douglas C. Tormey, Robert J. Gray — 1996
• Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.Rachel Schiff, Suleiman Massarweh, Jiang Shou — 2003
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.2005
• Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.Aron Goldhirsch, William C. Wood, Richard D. Gelber — 2003
• P81 Benefits of switching postmenopausal women withhormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 TrialM. Kaufmann, R. Jakesz, Michael Gnant — 2005
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.Paul E. Goss, James N. Ingle, Silvana Martino — 2004
• Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.Christina Davies — 2004
• Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.Brian J. Long, Danijela Jelovac, Venkatesh Handratta — 2004
• Markov Models in Medical Decision MakingFrank A. Sonnenberg, J. Robert Beck — 1993
• BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancerB. J. Thurlimann, Aparna Keshaviah, H.T. Mouridsen — 2005
• Aromatase inhibitors: rationale for use following antiestrogen therapy.W Yue, Richard J. Santen — 1996
• Anastozole (A) is superior to tamoxifen (T) in treatment of postmenopausal (PM) women with early breast cancer (EBC) - First results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial (on behalf of the ATAC Trialists' Group)M Baum — 2002
• Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen☆, ☆, ☆☆☆Abstracted from: Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.Christopher Davies — 2004

Cited by

• Aromatase Inhibitors in Early Hormone Receptor-Positive Breast CancerSarah Needleman, Jeffrey Tobias — 2008
• Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.А. П. Карпенко, О. А. Синяговская — 2006
• Adjuvant hormonal therapy for early-stage breast cancer.Amelia Zelnak, Ruth O’Regan — 2008
• Update in medical oncology for older patients: focus on breast cancer: management of early breast cancer.Sabrina Witherby, Hyman B. Muss — 2005
• Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings.Shelly S. Lo, Kathleen I. Pritchard, Patricia Robinson — 2009
• Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal WomenMonica Milani, Gautam Jha, David A. Potter — 2009
• Tamoxifen‐loaded liposomal topical formulation arrests hair growth in miceAmit Bhatia, Bhupinder Singh, Basant Amarji — 2010
• Prognostic factors of early distant recurrence in hormone receptor‐positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapyMarc Debled, Gaëtan MacGrogan, Véronique Brouste — 2007
• Aromatase Inhibitors: Changing the Face of Endocrine Therapy for Breast CancerAman U. Buzdar — 2006
• Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.Thomas E. Delea, Jonathan Karnon, Robert E. Smith — 2006
• [Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].Tamás Nagykálnai — 2008
• Switching to aromatase inhibitors in early breast cancer.Francesco Boccardo, A. Rubagotti — 2007
• Inappropriate ATAC on tamoxifen.G. Ucci — 2008
• Is oral metronomic cyclophosphamide (CTX) an effective palliative treatment for patients with metastatic breast carcinoma (ABC)? experience from a retrospective series of patientsHamouda Boussen, Giuseppe Bellavia, R. Agueli — 2008
• CYP2D6 polymorphisms and the impact on tamoxifen therapy.Jacob N. Beverage, Tristan M. Sissung, Amy Sion — 2007
• Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancerJames Mansell, Ian Monypenny, Anthony Skene — 2009
• Facilitating Breast-Conserving Surgery and Preventing Recurrence: Aromatase Inhibitors in the Neoadjuvant and Adjuvant SettingsEleftherios P. Mamounas — 2008
• Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.Patrick Neven, Robert Paridaens, Frédéric Amant — 2006
• Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients--longterm follow-up.Hans E. Fjøsne, Anne-Birgitte Jacobsen, Steinar Lundgren — 2008
• Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast CancerThe BIG 1-98 Collaborative Group — 2009

Related papers

• A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity.Paul M. Wood, L. W. Lawrence Woo, Anna Humphreys — 2005
• An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.Jeffrey Tobias, Anthony Howell — 2004
• A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal womenJuliette Murray, O. E. Young, Lorna Renshaw — 2009
• Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole.Robert Thomas, Sara Godward, Andreas Makris — 2004
• Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.Aman U. Buzdar — 2003
• New experimental models for aromatase inhibitor resistance.Shiuan Chen, Selma Masri, Yanyan Hong — 2007
• The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancerQing Lü, Yang Liu, Brian J. Long — 1999
• Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.Danijela Jelovac, Luciana F. Macedo, Olga Goloubeva — 2005
• An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestaneAman U. Buzdar, J.F.R. Robertson, W. Eiermann — 2002